Drug Type Fusion protein |
Synonyms MWN 105, MWN-105, MWN105 |
Target |
Mechanism FGF21R agonists, GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 1 | CN | 16 Dec 2024 | |
Obesity | Phase 1 | CN | 16 Dec 2024 | |
Nonalcoholic Steatohepatitis | Phase 1 | CN | - | |
Sleep Apnea, Obstructive | Preclinical | CN | 18 Apr 2024 | |
Hyperlipidemias | Preclinical | CN | - |